An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy

被引:39
作者
Keane, NM
Price, P
Lee, S
Stone, SF
French, MA
机构
[1] Royal Perth Hosp, Dept Clin Immunol & Biochem Genet, Perth, WA 6001, Australia
[2] Univ Western Australia, Dept Pathol, Perth, WA 6009, Australia
关键词
CD26 (DPPIV); CD30; HIV; interferon-gamma;
D O I
10.1046/j.1365-2249.2001.01647.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study evaluates serum CD26 (dipeptidyl peptidase IV, DPPIV) enzyme activity and serum levels of soluble CD30 as markers of T1 and T2 cytokine environments in HIV patients who achieved immune reconstitution after highly active antiretroviral therapy (HAART). Patients who had experienced inflammatory disease associated with pre-existent opportunistic infections after HAART (immune restoration diseases, IRD) were considered separately. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were compared with IFN-gamma production by PBMC cultured with cytomegalovirus (CMV) antigen in controls and patient groups. High sCD30 levels were associated with low IFN-gamma production after antigenic stimulation in control subjects and, to a lesser extent, in immune reconstituted HIV patients. There was no association between serum CD26 (DPPIV) enzyme activity and IFN-gamma production or sCD30 levels. Serum sCD30 levels and CD26 (DPPIV) enzyme activity were significantly increased in immune reconstituted patients with high HIV viral loads. Patients who had experienced CMV retinitis as an IRD had significantly higher sCD30 levels than all other patient groups. Hence, high sCD30 levels may be a marker of a T2 cytokine environment in HIV patients with immune reconstitution and are associated with higher HIV viral loads and a history of CMV associated IRD.
引用
收藏
页码:111 / 116
页数:6
相关论文
共 22 条
[1]   Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection [J].
Aziz, N ;
Nishanian, P ;
Taylor, JMG ;
Mitsuyasu, RT ;
Jacobson, JM ;
Dezube, BJ ;
Lederman, MM ;
Detels, R ;
Fahey, JL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04) :843-848
[2]   CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition [J].
Chilosi, M ;
Facchetti, F ;
Notarangelo, LD ;
Romagnani, S ;
DelPrete, G ;
Almerigogna, F ;
DeCarli, M ;
Pizzolo, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) :329-334
[3]   A T(H)1-]T(H)2 SWITCH IS A CRITICAL STEP IN THE ETIOLOGY OF HIV-INFECTION [J].
CLERICI, M ;
SHEARER, GM .
IMMUNOLOGY TODAY, 1993, 14 (03) :107-110
[4]   Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response [J].
Connick, E ;
Lederman, MM ;
Kotzin, BL ;
Spritzler, J ;
Kuritzkes, DR ;
St Clair, M ;
Sevin, AD ;
Fox, L ;
Chiozzi, MH ;
Leonard, JM ;
Rousseau, F ;
Roe, JD ;
Martinez, A ;
Kessler, H ;
Landay, A .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :358-363
[5]   In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells [J].
DElios, MM ;
Romagnani, P ;
Scaletti, C ;
Annunziato, F ;
Manghetti, M ;
Mavilia, C ;
Parronchi, P ;
Pupilli, C ;
Pizzolo, G ;
Maggi, E ;
DelPrete, GF ;
Romagnani, S .
JOURNAL OF LEUKOCYTE BIOLOGY, 1997, 61 (05) :539-544
[6]   PREFERENTIAL EXPRESSION OF CD30 BY HUMAN CD4(+) T-CELLS PRODUCING TH2-TYPE CYTOKINES [J].
DELPRETE, G ;
DECARLI, M ;
ALMERIGOGNA, F ;
DANIEL, CK ;
DELIOS, MM ;
ZANCUOGHI, G ;
VINANTE, F ;
PIZZOLO, G ;
ROMAGNANI, S .
FASEB JOURNAL, 1995, 9 (01) :81-86
[7]  
French M A, 2000, HIV Med, V1, P107, DOI 10.1046/j.1468-1293.2000.00012.x
[8]  
GIANCOMELLI R, 1998, CLIN EXP IMMUNOL, V111, P532
[9]   Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals [J].
Hosono, O ;
Homma, T ;
Kobayashi, H ;
Munakata, Y ;
Nojima, Y ;
Iwamoto, A ;
Morimoto, C .
CLINICAL IMMUNOLOGY, 1999, 91 (03) :283-295
[10]   Assessment of immune function by lymphoproliferation underestimates lymphocyte functional capacity in HIV patients treated with highly active antiretroviral therapy [J].
Keane, NM ;
Price, P ;
Stone, SF ;
John, M ;
Murray, RJ ;
French, MA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) :1991-1996